Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.63
+0.31 (5.83%)
Sep 14, 2026, 3:21 PM EDT - Market open
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$112,589
Profits / Employee
-$1,037,507
Market Cap
828.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 73 | 9 | 14.06% | 69 | 4 |
| Dec 31, 2024 | 64 | -27 | -29.67% | 61 | 3 |
| Dec 31, 2023 | 91 | -14 | -13.33% | 86 | 5 |
| Dec 31, 2022 | 105 | 28 | 36.36% | 100 | 5 |
| Dec 31, 2021 | 77 | 17 | 28.33% | 72 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| 4D Molecular Therapeutics | 196 |
| Aura Biosciences | 113 |
| Annexon | 92 |
| Silence Therapeutics | 88 |
| Crescent Biopharma | 69 |
| Candel Therapeutics | 55 |
| Climb Bio | 29 |
ACRS News
- 4 days ago - Aclaris Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 11 days ago - Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Aclaris Therapeutics initiated with a Buy at Canaccord - TheFly
- 5 weeks ago - Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib - TheFly
- 5 weeks ago - Aclaris Therapeutics files automatic mixed securities shelf - TheFly
- 5 weeks ago - Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c) - TheFly
- 5 weeks ago - Aclaris Therapeutics Earnings release: Q2 2026 - Filings